hkr.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement
The Swedish Institute for Health Economics, Lund.
The Swedish Institute for Health Economics, Lund.
Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund.
Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund.
Visa övriga samt affilieringar
2006 (Engelska)Ingår i: Parkinsonism & Related Disorders, ISSN 1353-8020, E-ISSN 1873-5126, Vol. 12, nr 7, s. 443-452Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to euro12000-64000 according to cost-per-QALY thresholds of euro38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.

Ort, förlag, år, upplaga, sidor
2006. Vol. 12, nr 7, s. 443-452
Nyckelord [en]
Parkinson’s disease, Cost-effectiveness, Outcomes, Modeling, Cell therapy
Nationell ämneskategori
Neurologi
Identifikatorer
URN: urn:nbn:se:hkr:diva-12320DOI: 10.1016/j.parkreldis.2006.04.006ISI: 000241605700007PubMedID: 16798054OAI: oai:DiVA.org:hkr-12320DiVA, id: diva2:732156
Tillgänglig från: 2014-07-03 Skapad: 2014-07-03 Senast uppdaterad: 2017-12-05Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Hagell, Peter

Sök vidare i DiVA

Av författaren/redaktören
Hagell, Peter
I samma tidskrift
Parkinsonism & Related Disorders
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 45 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf